Ben Arye Barak 4
4 · NovoCure Ltd · Filed Jul 1, 2026
Research Summary
AI-generated summary of this filing
NovoCure (NVCR) GC Ben Arye Barak Buys 1,299 Shares
What Happened
Ben Arye Barak, General Counsel of NovoCure Ltd (NVCR), acquired 1,299 ordinary shares on June 30, 2026. The reported purchase price was $11.15 per share for a total value of $14,484. This was an acquisition under NovoCure’s 2025 Employee Share Purchase Plan (ESPP), so it is a purchase rather than a sale.
Key Details
- Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (timely).
- Shares acquired: 1,299 at $11.15 each; total reported value $14,484.
- Shares owned after transaction: Not disclosed in this filing.
- Footnotes: Reporting person voluntarily reported the ESPP purchase for the Jan 1–Jun 30, 2026 purchase period. Shares were purchased at a discounted price (85% of the closing price on Jan 1, 2026). The transaction is exempt under Rule 16b-3(c).
- Filing timeliness: No late filing indicated (transaction 6/30, filed 7/1).
Context
This was an employee share purchase (ESPP) — employees commonly buy company stock at a discount through such plans. Purchases can be viewed as a positive signal, but they do not necessarily indicate insider views on near-term company performance. The filing is factual and does not show any option exercises, sales, or transfers.
Insider Transaction Report
- Award
Ordinary Shares
[F1][F2]2026-06-30$11.15/sh+1,299$14,484→ 243,752 total
Footnotes (2)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
- [F2]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.